Benjamin Zebley, MD

Highlights

1
Biological psychiatry · 2025
BZBenjamin Zebley CLConor Liston
PMID: 40155118DOIFirst author
2
Biological psychiatry global open science · 2021
BZBenjamin Zebley CJCharles Joseph LynchRMRachel MikofskyCLConor Liston
PMID: 34704087PMCID: PMC8529885DOIFirst author7 citations

15

4 grants

Co-I
An open-label trial of a novel prefrontal cortical interneuron-targeting antidepressant medication combination to achieve rapid antidepressant responses with minimal side effects
Hope for Depression Research Foundation · 2026–2028
HDRF 262807-01
Co-I
Maintenance rTMS for depression (Maitr-De)
National Institute of Mental Health · 2025–2027 · via University of California, San Diego
R61MH138647-01
Co-I
Efficacy of biomarker-guided rTMS for treatment resistant depression
National Institute of Mental Health · 2019–2027
R01MH118388-01
MPI
Biomarker-Guided Antidepressant Selection for Treatment-Resistant Depression
National Institute of Mental Health · 2024–2026
UG3MH137656-01

Completed grants (2)

Co-I
The Effects of Stanford Accelerated Intelligent Neuromodulation Therapy on Explicit and Implicit Suicidal Cognition
National Institute of Mental Health · 2023–2025 · via Magnus Medical, Inc.
R01MH125160-03
KP
WELLCOME LEAP MARFA Master Contract - Personalized Therapeutic Neuromodulation for Anhedonic Depression
Wellcome Leap, Inc. · 2021–2024
WL 221649-01

1

Completed & closed trials (1)

PI
Follow-On for Randomized Trial SAINTÂ® Neuromodulation System for the Treatment of Depression in an Inpatient Setting
Magnus Medical, Inc. · IRB STUDY CLOSURE (as of 2025)